Europe Next Generation Sequencing Market Report by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening, and Others), Technolog

Europe Next Generation Sequencing Market Report by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening, and Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Read Time Sequencing, Nanopore Sequencing, and Others), End-Users(Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), Country and Company Analysis 2024-2032

Europe Next Generation Sequencing Market Outlooks

Next Generation Sequencing (NGS) is a powerful technique employed for decoding large sample sequences in parallel and in a more timely and cost-effective method compared to other methods. Unlike the conventional methods of sequencing, NGS has the capacity of sequencing millions of DNA fragments within a short span, cost-effective as well as highly accurate. It also too has so many uses for example in the genetic research, genetic medicine or even just in testing diseases. Due to NGS genomics, it is easier to understand the complexities of data, analyze mutations and even perform molecular analysis of diseases.
In European countries NGS is be used broadly in health services and in research. This is commonly employed in cancer research to identify genes, as well as mutations and to design treatment to enhance patient care. Moreover, NGS is being used for diagnosis of RDs where it helps in acquiring faster rates of diagnosis of genetic disorders. Many European health systems and research institutions interest in NGS for personalized medicine, infectious diseases monitoring, and population genomics improving the precise medicine in Europe.
Currently, there is growth in the incidence of cancer across the globe, where 4.4 million new cancer cases in Europe in 2020 with this number anticipated to reach 4.9 million by 2030. The main forms of cancer are lung, breast, colon, prostate and rectum. The performance of NGS in the management of NSCLC and in cancer research as a whole has led with the enhanced elucidation of molecular basis of individual cancers.


Growth Driver of the Europe Next Generation Sequencing Market

Advancements in Genomic Research

Biological and genomic development is another reason for market growth in the European Next Generation Sequencing (NGS). Sequencing processes have also benefitted from improvements in technology since these processes are faster, more accurate and cheaper to accomplish. These are enabling the researchers to work on intricate information involving the genetics and to discover new biomarkers as well as the understanding of the causes of diseases based on genetics. Advancements in this area of the credit has enhanced discoveries in personalized medicine, cancer analysis, and clinical uncommon genetic disorders. Since Europeans research institutions and ‘biotech firm make use of these technologies, the market for NGS services and products expands thus contributing to growth in the market.

Increasing Prevalence of Genetic Disorders

Currently, EC increase in frequency of various genetic disorders, which leads to the growing demand for NGS. With a growing number of patients with genetic disorders – inherited cancers, rare and congenital diseases – more sharply, differentiated diagnostics and treatment plans are required. Next-generation sequencing gives extensive and precise genetic data for the formulation of these disorders’ diagnosis and treatment. This demand for the genetic testing and moving towards personalized medicine is driving the NGS market since health care providers are in search of better diagnostic tools to serve their client better.

Expanding Applications in Personalized Medicine

Expansion across applications in Personalized medicine is identified as a primary growth factor in the European NGS market. As one of the leading products offering personalized medicine where treatment depends on the genetic make-up of the patient, NGS technologies provides the necessary and adequate genetic information. Personalized medicine strategies and targeted therapy applications can be accelerated through NGS since accurate determination of associations between genetic variations and therapeutic outcomes is achievable. It has been observed that with the advent of personalized medicine in the Europe, the healthcare facilities are now investing more in NGS solutions for precision in diagnosis and treatment of the patients and this has fueled the growth of the market.

Germany Next Generation Sequencing Market

Germany’s NGS demand is set to continue growing as more organizations and patients take advantage of genomics and incorporate them into their medical strategies. The improvement in research capabilities and investment on biotechnology of Germany helped in the adaptation of NGS on different study area such as cancer studies, genetic disease, and individualized medicine. Analyzing the German market, the most important advantage of NGS is its possibility of high-throughput analysis, which helps research institutions and hospitals in discovering new biomarkers. Besides, grants and subsidies provided by governments for genomic research also contributes to the growth of the market. With Germany being a key player in the global healthcare industry and with more emphasis being laid on developing innovative healthcare services in Germany and especially on individualized treatment systems, the Germany NGS market is expected to experience considerable growth in the years to come owing to continuing technological advancement as well as its increasing clinical applications. This segment in 2024 is expected to dominate the research and other applications segment in Europe NGS market. The rise in the number of laboratories that are adopting sequencing-based tests, the increasing market for personalized drugs, the use of NGS for research and the rising incidences of genetic diseases. For instance, based on the data from the German Center for Lung Research, July 2024, about 2,500 newborns were diagnosed with cystic fibrosis in 2022.

Europe Next Generation Sequencing Company Analysis

The top companies in the European Next-Generation Sequencing Market are Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, QIAGEN N.V, Roche, Bio-Rad Laboratories, Inc., Takara Bio Inc., Hamilton Company, Geneious, and BioMérieux SA.

Europe Next Generation Sequencing Company News

Jul 2024, Permanent reimbursement for next-generation sequencing (NGS) in oncology launched in Belgium.
On August 2023, Almac Diagnostic Services, a member of the Almac Group, invested in expanding its NextNext-Generation Sequencing capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus instrument in Northern Ireland and the whole island of Ireland.
In June 2024, Illumina Inc. announced that it has completed integrating the latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.

Product –Market breakup in 3 viewpoints:

1. Instruments
2. Reagents & Consumables
3. Services

Application – Market breakup in 5 viewpoints:

1. Diagnostics
2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others

Technology – Market breakup in 5 viewpoints:

1. Sequencing by Synthesis
2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others

End-Users –Market breakup in 4 viewpoints:

1. Academic and Clinical Research Centers
2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others

Countries – Europe Next-Generation Sequencing (NGS) Market of 15 Countries:

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Russia
9. Poland
10. Greece
11. Norway
12. Romania
13. Portugal
14. Turkey
15. Rest of Europe

All the Key players have been covered from 5 Viewpoints:

1. Overviews
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue

Company Analysis:

1. Illumina
2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious,
10. BioMérieux SA.